Abstract:Objective To investigate the efficacy and safety of the cetuximab combined with chemotherapy for patients with metastasis from colorectal cancer whose K-Ras status were wild type and explore the factors that may affect the efficacy and prognosis. Methods Retrospectively collected the clinical data of 90 patients with metastasis from colorectal cancer whose K-Ras status were wild type. Cetuximab 400mg/m2 was intravenously given at first dose and maintenance at 250mg/m2 every week or 500mg/m2 every two weeks. Combined chemotherapy regimen included, irinotecan-based chemotherapy(FOLFIRI or XELIRI or irinotecan monotherapy), oxaliplatin-based chemotherapy( FOLFOX or XELOX) ,other regimens, such as 5-FU/leucovorin or capecitabine monotherapy. The ef-ficacy and safety of each line of chemotherapy was summarized and assessed, and the relationship between clinicopathology features, treatment characteristics and efficacy, explore the factors associated with prognosis were analyzed retrospectively. Results The median duration treatment of cetuximab was 16 weeks( 6-44 weeks) . And in all patients the objective response rate( ORR) was 45?6%,and the disease control rate( DCR) was 87?8%. The DCR in first line treatment was 51?6% better than in second line, whose was 40?0%, and the DCR in third line was 18?2%. The age, location of primary tumor, treatment time of cetuximab might affect the efficacy fo cetux- imab plus chemotherapy. In the 90 patients, recurrent metastases were occurred in 82 cases( 91?1%) and death in 60 cases( 66?7%) . The median PFS( mPFS) was 7?8 months and median OS( mOS) was 22?5 months. In the first line treatment of cetuximab plus chemo-therapy, mPFS was 9?1 months and mOS was 27?6 months. In second line treatment mPFS was 7?7 months and mOS was 14?5 month. in third line mPFS was 2?9 months and mOS was 6?7 months. Univariate survival analysis showed that the location of primary tumor, early tumor response and treatment time of cetuximab were related to PFS and OS of the patients, and the metastasis scope was related to the OS of patients. Using the Cox multivariate hazards model to analysis the clinicopathological factors, which showed that the loca-tion of primary tumor and early tumor response were the independent risk factors affecting the PFS of patients, the metastasis scope was the independent risk factor affecting the OS of patients. The most common adverse reaction related to cetuximab is acne-like rash, the side effects associated with chemotherapy mainly were diarrhea, nausea, vomiting, bone marrow suppression. After symptomatic treat-ment, patients can tolerate. Conclusion Cetuximab combined chemotherapy in each line treatment of patients with metastases from colorectal cancer can get great efficacy, and the adverse reactions can be tolerated. The location of primary tumor might be the predic-tors of the efficacy, and it is also associated with the prognosis of the patients. As ETS Shows that early tumor response could be one of the outcome indicators of mCRC.

Combination of Cetuximab and Pp242 Synergistically Suppress the Progression of Wild-Type Kras Colorectal Carcinoma

A dual-targeted molecular therapy of PP242 and cetuximab plays an anti-tumor effect through EGFR downstream signaling pathways in colorectal cancer

Combination Of Mtor And Egfr Kinase Inhibitors Blocks Mtorc1 And Mtorc2 Kinase Activity And Suppresses The Progression Of Colorectal Carcinoma

Preclinical Activity Of The Rational Combination Of Apatinib In Combination With Cpt-11 In Kras-Mutant Colorectal Cancer Patient-Derived Xenograft Model

Combine MEK Inhibition with PI3K/mTOR Inhibition Exert Inhibitory Tumor Growth Effect on KRAS and PIK3CA Mutation CRC Xenografts Due to Reduced Expression of VEGF and Matrix Metallopeptidase-9

Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer

Combination of Cetuximab and Rapamycin Enhances the Therapeutic Efficacy in Hepatocellular Carcinoma.

Combined Analysis Of Egfr And Pten Status In Patients With Kras Wild-Type Metastatic Colorectal Cancer

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer

Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.

Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis

Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status

Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Efficacy analysis of cetuximab plus chemotherapy for K-Ras wild-type colorectal cancer with metastases

[Effect of KRAS Mutation on Efficacy of Cetuximab Combined with Chemotherapy in Advanced Colorectal Cancer Patients].

Efficacy Of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy And Its Effects On K-Ras Mutations In Advanced Colorectal Cancer

[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].

Cetuximab enhances the efficiency of irinotecan through simultaneously inhibiting the MAPK signaling and ABCG2 in colorectal cancer cells

Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6

K-ras status and efficacy of cetuximab-containing regimen in the treatment of patients with metastatic colorectal cancer